BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

Position statement from the North American Menopause Society on Testosterone Therapy on post menopausal women.

Position Paper

Biosante have no doubt been examining the following psychosocial issues and psychological disorders in the subset analysis of Libigel's efficacy trials

Psychosocial issues
Previous attitudes toward sex
Social customs and religious beliefs regarding sex
Poor partner relationship
Feelings toward partner
Length of relationship
Partner’s decreased capacity for sexual activity
Partner’s loss of interest in sex
No available partner
Life stressors from work, family, relationships
Negative body image

Psychological disorders
Depression
Anxiety
Other psychiatric illness

Medical conditions
Vaginal atrophy
Vasomotor symptoms
Incontinence
Chronic illness, including cardiovascular disease, diabetes mellitus, arthritis, renal failure
Cancer, particularly gynecologic or breast cancer

Pharmacologic agents
Psychotropics: selective serotonin-reuptake inhibitors, tricyclic antidepressants, benzodiazepines, barbiturates, anxiolytics, sedatives
Cardiovascular: beta-blockers, clonidine, methyldopa, spironolactone
(which has antiandrogenic properties)
Hormones: gonadotropin-releasing hormone agonists and antagonists, corticosteroids,
antiandrogens
Recreational drugs: alcohol, marijuana, cocaine, heroin, methadone


This is the Clinical trial exclusion criteria
A history of allergic reactions to androgens (oral or patch), topical alcohol, or any component of the formulation
Any systemic skin diseases or local skin abnormalities in the area of application
Diagnosed with another primary female sexual dysfunction (e.g., Sexual Aversion Disorder, Female Sexual Arousal Disorder).
A medical condition that could affect or interfere with sexual function
Using a systemic transdermal gel or cream estrogen therapy.